Результаты поиска

The association between agranulocytosis and 30-day mortality in patients with hematological disorders and bloodstream infections: A retrospective cohort study.

Agranulocytosis and bloodstream infections (BSIs) are common complications in patients with hematological disorders and they are life-threatening. This study aims to explore the association between agranulocytosis and 30-day mortality in individuals with hematological disorders and BSIs. In this retrospective cohort study, neutrophil levels were measured in patients presenting with fever and diagnosed with a hematological disorder at Tongde Hospital of Zhejiang Province between March 2018 and August 2023. The primary outcome was all-cause 30-day mortality. Multivariate Cox proportional hazard

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

Therapy-related myeloid neoplasms (t-MN), including myelodysplastic neoplasms (t-MDS) and acute myeloid leukemia (t-AML), have emerged as significant late complications after CAR T cell therapy. We retrospectively analyzed 539 patients with B cell lymphoma treated with CD19 directed CAR T cell therapy across four French centers. Cumulative incidences of t-MN was estimated with relapse or death treated as competing risk. Univariate and propensity score matching (PSM) analyses were conducted to assess risk factors with age and the number of prior treatments as covariates. After a median follow-u

Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India - Knowing the Unknown.

To evaluate the incidence, clinical characteristics and outcomes of second primary malignancies (SPM) in Multiple myeloma patients post autologous stem-cell transplant (ASCT). This is a report of myeloma patients from a prospectively maintained database who underwent ASCT between 1st March, 2007 to 31st December, 2022. Baseline characteristics, details of induction, transplant and post-transplant maintenance therapy of these patients were retrieved. Details of treatment received for SPM, and outcomes were also obtained. In total,178 patients underwent 192 ASCTs (14 patients with two ASCTs). Of

Review of Paraneoplastic Syndromes in Children with Malignancy.

A paraneoplastic syndrome (PNS) is a set of symptoms and signs that can accompany the formation of a cancer but is not due to its direct infiltration or metastasis. PNS results from the secretion of peptides or hormones by tumor cells or from an immunological cross-reaction between the tumor antigens and host antigens. In the adult population, PNS affects up to 15% of patients with cancer, but data on pediatric patients remain lacking. The remarkable fact is that PNS can precede an oncology diagnosis, even by months or years. PNS can involve virtually any organ of the human body. In children,

International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.

As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the number of HCTs performed annually continues to rise. Parallel improvements in HCT techniques and supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pretransplantation, peritransplantation, and post-transplantation exposures and other underlying risk factors. Guidelines for screening and preventive practices for HCT survivors were originally p

Are We Ready For "Triplet" Therapy in Higher-Risk MDS?

Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidities. Outside of transplant, azacitidine and decitabine remain the only disease-modifying therapies, and are palliative in nature. Recent interest has grown in extending combination chemotherapies used to treat acute myeloid leukemia (AML) to patients with MDS, including novel combination chemotherapy "doublets" and "triplets." In this review, we discuss consi

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

Multiple myeloma (MM) is characterized by recurrent relapses. Consequently, patients receive multiple therapy lines, including alkylating agents and immune modulators, which have been associated with secondary malignancies such as myelodysplastic syndrome (MDS). Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CART) therapy is efficacious in patients with relapsed/refractory (R/R) MM. However, the long-term complications, particularly MDS, are not well understood. Whether CART therapy causes or promotes MDS has not been thoroughly investigated. In this study, we explored

Identification of Potential Key Genes and Regulatory Markers in Essential Thrombocythemia Through Integrated Bioinformatics Analysis and Clinical Validation.

IntroductionEssential thrombocytosis (ET) is a group of myeloproliferative neoplasms characterized by abnormal proliferation of platelet and megakaryocytes. Research on potential key genes and novel regulatory markers in essential thrombocythemia (ET) is still limited.MethodsDownloading array profiles from the Gene Expression Omnibus database, we identified the differentially expressed genes (DEGs) through comprehensive bioinformatic analysis. GO, and REACTOME pathway enrichment analysis was used to predict the potential functions of DEGs. Besides, constructing a protein-protein interaction (P

Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.

PurposeThe essence of this scholarly work was to carefully outline the key factors intensifying the virulence and protracted contagion of COVID-19, particularly among individuals afflicted with hematologic malignancies (HM), in an epoch predominantly governed by the Omicron variant.MethodsAdults with HM diagnosed with COVID-19 from November 2022 to February 2023 were monitored in this retrospective study. Patient blood samples yielded biochemical data, and COVID-19 was confirmed through RNA or antigen testing. The factors affecting severity and infection duration were examined using both univa

Bleeding frequency during physiotherapy in thrombocytopenic patients undergoing hematopoietic stem cell transplantation.

BACKGROUND: During hematopoietic stem cell transplantation (HSCT) the patients perform activities of low and moderate intensity because have reduced hematological lineages, leaving them susceptible to hemorrhagic events. The objective of this study was to describe the frequency of bleeding events, severity, and possible association with physical exercise in thrombocytopenic patients. METHODS: A retrospective study with seventy-seven HSCT patients hospitalised, that had a platelet count ≤ 50,000 /μL and received physical exercise during physiotherapy intervention. RESULTS: Regarding bleeding

Следующие биомаркеры в нескольких миеломах: расширение диагностики, стратификация рисков и достоверная терапия за пределами нынешних руководящих принципов.

Множественная миелома (ММ) — онкогематологическая неоплазма, характеризующаяся аномальным распространением неопластических плазменных клеток в костном мозге и чрезмерным сечением моноклонных антител в кровоток. Примерно 3 в адрес 5% :: пациенты, имеющие разновидность болезни, в которой нет секреции моноклонных белков, характеризующие несекретарскую картину MM. Она имеет весьма сложную и разнородную генетическую сигнатуру, позволяющую классифицировать болезнь в предмалярные организмы и симптомные формы. В этом контексте был проведен комплексный обзор описательной части, охватывающий геномные, э

Regional, demographic and temporal trends in anemia and malignant cancer-related mortality in U.S. older adults: a nationwide CDC WONDER analysis (1999-2020).

PurposeAnemia and malignancy concurrently contribute to reduced quality of life, treatment intolerance, and increased morbidity and mortality, disproportionately affecting older adults, socioeconomically disadvantaged groups, and minority populations. Despite its clinical importance, national patterns and population-level disparities in the mortality burden associated with this comorbidity remain poorly characterized. This study aims to examine mortality trends associated with concurrent anemia and malignancy in the United States using CDC WONDER (Centers for Disease Control and Prevention Wid

Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.

PURPOSE: To evaluate anticoagulant trends and clinical outcomes in the management of cancer-associated thrombosis (CAT) within Thailand, an upper-middle-income country (UMIC). METHODS: This multicenter retrospective cohort study included adult patients with cancer diagnosed with venous thromboembolism (VTE) hospitalized in Thailand from 2017 to 2021. Anticoagulants were classified as low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and warfarin. Prescription trends were assessed, and patients were followed for 1 year, or until 2022 to evaluate outcomes. The primary eff

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.

Secondary antibody deficiencies (SAD) may require immunoglobulin replacement therapy (IgRT). While the intravenous route (IVIG) is broadly considered effective in SAD, the use of subcutaneous immunoglobulins (SCIG) is mainly adopted from the experience in primary antibody deficiencies (PAD), where SCIG have been shown to perform as effective as IVIG. However, evidence-based data on SCIG administration in SAD patients are still insufficient. Herein we retrospectively evaluated the efficacy and safety profile of SCIG treatment in 131 SAD patients as compared to a group of 102 PAD patients. We fo

Совпадение в полном тексте источника
… Also, the fact that most of our NHL patients who suspended SCIG RT experienced infectious exacerbations suggests not to restrain indication to SCIG in hematologic neoplasms only to the aforementioned groups, in agreement with the latest EMA guidelines about IVIG use [ 12 ]. … There were no statistic significant difference between initial (panel A) and steady state (panel B) Ig RT dosage in patients with SAD due to hematologic neoplasm (n = 111). (A) One way ANOVA test, F(2, 108) = 0.7698, p = .4656) and (B) One way ANOVA test, F(2, 108) = 1.016, p = .3654). …

Exploring the landscape of palliative care provision for black patients with hematologic cancers: A scoping review.

ObjectivesPatients with cancer benefit greatly from receiving palliative care (PC), improving their overall survival and quality of life. Despite its benefits, PC is underutilized among patients with hematologic malignancies (HMs), particularly among Black patients, who face higher symptom burdens and lower survival rates compared to White patients. The purpose of this review was to identify and describe what is known about PC use among Black HM patients in the United States.MethodsThis review was conducted using the Joanna Briggs Institute approach for scoping reviews and included a search of

Patient-reported patterns of follow-up care in the 'Aftercare in Blood Cancer Survivors' (ABC) study.

BACKGROUND: Follow-up care provides long-term support for cancer survivors. Little is known about follow-up care in hematologic malignancies. METHODS: Our questionnaire-based study included blood cancer survivors diagnosed at the University Hospital of Essen before 2010, with a ≥ 3-year interval since the last intense treatment. The primary goal of the retrospective study was the identification and characterization of follow-up institutions. RESULTS: Of 2386 survivors meeting the inclusion criteria, 1551 (65.0%) consented to participate, with a follow-up duration > 10 years in 731. The unive

Monitoring NK cell activity in patients with hematological malignancies.

Natural killer (NK) cells are lymphocytes of the innate immune system that can recognize and kill various types of malignant cells. Monitoring the activity of peripheral NK cells in patients affected by hematological malignancies may provide prognostic information or unveil ongoing tumor-specific immune responses. Moreover, further insights into the biology of NK cells might also promote the development of novel strategies for stimulating their anticancer activity. Here, we review the main methods to monitor phenotypic and functional NK cell properties in cancer patients, focusing on individua

Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.

Cytokine-induced killer (CIK) cells are a heterogeneous population of immune effector cells that feature a mixed T- and Natural killer (NK) cell-like phenotype in their terminally-differentiated CD3+CD56+ subset. The easy availability, high proliferation rate and widely major histocompatibility complex (MHC)-unrestricted antitumor activity of CIK cells contribute to their particularly advantageous profile, making them an attractive approach for adoptive immunotherapy. CIK cells have shown considerable cytotoxicity against both solid tumors and hematological malignancies in vitro and in animal

Использование стационарной гемато-онкологической службы до, во время и после COVID-19 Ограничения в румынском Третичном центре.

Введение Болезнь коронавируса 2019 (В тыс.COVID-19) пандемия помешала диагностике и лечению рака, однако имеющиеся в больницах данные об использовании стационарного гемато-онкологического обслуживания в Восточной Европе остаются ограниченными. В ходе этого исследования была проведена оценка того, как период пандемии повлиял на улавливание, диагностическое подтверждение, повторное стационарное лечение, госпитализацию и больничные дни среди взрослых с лимфомой, лейкемией или множественными миеломой в румынском высшем центре. В больнице скорой помощи округа Сибиу, Сибиу, Румыния, был проведен рет

Совпадение в полном тексте источника
… The Haematological Malignancy Research Network attributed 486 of 18,883 deaths in premalignant and malignant hematologic neoplasms to COVID-19 [ 30 ], while the Croatian KroHem cohort reported adverse outcomes among patients with lymphoid malignancies in the pre-Omicron period [ 31 ]. …

Двустороннее участие грудных вскармливаний в множестве миелом: доклад о реалистическом деле.

Грудная плазмоцитома представляет собой редкое дополнительное проявление множественной миеломы (ММ). Этот случай представляет собой первичную экстрамульгальную плазмоцитому и переход к MM с участием груди после 12 годы обнаружения болезни. Пациент - это 54-year-old Женщина, у которой изначально был правый патологический перелом плечевой кости, оказавшийся основной дополнительной плазмоцитомой. Она получила химиотерапию и получила ремиссию. Six Спустя несколько лет болезнь повторилась как масса в грудине, которая была обработана радиацией и химиотерапией, но без улучшения. Затем болезнь перешла